Cargando…
Correction to: Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial
Autores principales: | Villar, Juan Carlos, Herrera, Víctor Mauricio, Carreño, Juan Guillermo Pérez, Herrera, Eliana Váquiro, Domínguez, Yeny Zulay Castellanos, Vásquez, Skarlet Marcell, Cucunubá, Zulma Milena, Prado, Nilda Graciela, Hernández, Yolanda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701118/ https://www.ncbi.nlm.nih.gov/pubmed/31429793 http://dx.doi.org/10.1186/s13063-019-3630-y |
Ejemplares similares
-
Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial
por: Villar, Juan Carlos, et al.
Publicado: (2019) -
Sensibilidad in vitro a benznidazol, nifurtimox y posaconazol de cepas de Trypanosoma cruzi de Paraguay
por: Acosta, Nidia, et al.
Publicado: (2020) -
Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas’ disease
por: Jackson, Yves, et al.
Publicado: (2020) -
Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
por: Rolon, Miriam, et al.
Publicado: (2022) -
Genotoxicity Revaluation of Three Commercial Nitroheterocyclic Drugs: Nifurtimox, Benznidazole, and Metronidazole
por: Buschini, Annamaria, et al.
Publicado: (2009)